GlassScriptPhysician profile
Anila Khan
NPI 1063415545
$3,018.93
in general payments reported to CMS, 2019-2025
22 companies · $810 in 2025
The $810 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $331 · 2021: $326 · 2022: $470 · 2023: $251 · 2024: $624 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,614.93 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $587.66 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $456.41 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $369.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $355.60 | 2023-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $241.44 | 2021-2024 | |
| Abbott Laboratories | $172.41 | 2021-2025 | Ensite, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.58 | 2022-2025 | Jardiance |
| Astellas Pharma US INC | $118.84 | 2020-2025 | Veozah |
| Mannkind Corporation | $112.73 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.73 | 2019-2020 | |
| Glaxosmithkline, LLC. | $87.53 | 2019-2023 | Shingrix |
| Exact Sciences Corporation | $67.40 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $35.48 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.45 | 2022 | |
| Sumitomo Pharma America, INC. | $26.23 | 2024 | Gemtesa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $22.28 | 2024 | |
| Eisai INC. | $20.81 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.80 | 2021 | |
| Alkermes, INC. | $13.80 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.07 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.00 | 2021 | |
| Althera Pharmaceuticals LLC | $4.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anila Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.